XCancer

Optimisation and Safety of an Innovative Nuclear Medicine Treatment: Clinical and Dosimetric Study of Patients Treated With 177Lu-PSMA-617 for Prostate Cancer.

Description:

Single-centre, retrospective and prospective observational study. This study aims to evaluate the dose delivered by radiation to the tumour and organs at risk, as a factor predicting response and the appearance of toxicities. Dosimetric calculations are made for each treatment using scintigraphic images acquired following injection of 177Lu-PSMA-617.

Sponsor:

Institut Bergonié

Phase:

N/A

Contacts:

Nadège ANIZAN

n.anizan@bordeaux.unicancer.fr

+33556333347

Government Study Link:

NCT06700057 - Click here to see study on

ClinicalTrials.gov

177Lu-PSMA-617

Isotope(s):
Target(s):
  • PSMA
Chelator: DOTA